RALOXIHEAL 60MG 10 tablets

Raloxiheal 60 mg – Excellent Quality

Raloxiheal 60 mg is manufactured by Healing Pharma and contains Raloxifene, a relatively new anti-estrogen approved for the treatment of estrogen-related medical conditions, including osteoporosis and estrogen-responsive breast cancer. Similar to Nolvadex, anabolic steroid-using bodybuilders frequently take Raloxiheal 60 mg as a supplement to battle and/or avoid Estrogen-related side effects and issues (Tamoxifen). Although Raloxiheal 60 mg / Raloxifene is not as commonly used for this reason as Nolvadex, research shows that it is nearly as effective. Despite the fact that Raloxifene lacks the research and clinical data that more established SERMs like Nolvadex have, it is rapidly gaining popularity and interest within the bodybuilding and anabolic steroid-using communities. Many within these communities have viewed Raloxifene as a slightly safer alternative, although these claims are currently unfounded.

Raloxiheal 60 mg / Raloxifene doses for the treatment and prevention of estrogen-related adverse effects associated with anabolic steroid usage are usually greater than those for better-known SERMs such as Nolvadex, needing larger Raloxifene doses to counteract and regulate estrogenic side effects. In the arena of anabolic steroid usage, raloxifene is primarily employed for the treatment of gynecomastia, with rather little efficacy against additional estrogenic side effects. This is because, as stated in the introduction of this profile, Raloxifene works by reducing Estrogen’s activity in specific tissues rather than lowering the body’s total Estrogen levels. This is a property shared by all SERMs, and it is how they all operate. Users of anabolic steroids should keep this in mind, since attempts to prevent excess estrogenic side effects such as bloating and fluid retention with Raloxifene dosages will ultimately fail. In contrast, aromatase inhibitors are more suited to these aims.

In addition to its anti-estrogen properties, Raloxiheal has been shown to be an effective endogenous Testosterone booster, with studies demonstrating a 20% rise in blood Testosterone levels with 120mg of Raloxifene daily. Although not as efficient as Nolvadex, this quantity and degree of endogenous Testosterone stimulation is sufficient to warrant its usage as a feasible adjunct during post-cycle treatment (PCT).

Dosages of Raloxifene for Medical Use

The FDA has authorized Raloxiheal 60 mg (Raloxifene) for the main purpose of treating and preventing osteoporosis by lowering bone resorption and increasing ossification in bone tissue (bone formation). Raloxifene is primarily used to treat osteoporosis in postmenopausal women. Raloxifene is also used to treat Estrogen-responsive breast cancer in postmenopausal women; its Estrogen antagonistic activity prevents Estrogen from inducing breast cancer.

The recommended daily dose of Raloxiheal for the treatment of osteoporosis and female breast cancer is one 60 mg capsule. The 60mg dose of raloxifene can be taken with or without meals.

Doses of Raloxifene During Use of Anabolic Steroids

For instance, Raloxiheal does not fall into any of the three user groups (beginning, moderate, or advanced) that are typically established and included in standard chemical and pharmacological profiles. This is due to the fact that Raloxifene is a medicine used to avoid or lessen specific Estrogen-related adverse effects associated with the use of aromatizable anabolic steroids, and not for performance improvement.

Raloxiheal dosages can also be used to increase endogenous Testosterone secretion in males, allowing this chemical to be used as an adjunct treatment during PCT (Post Cycle Therapy) phases following an anabolic steroid cycle, although this is uncommon and unlikely to result in significant performance improvements.

Raloxiheal dosages are often used either to avoid the development of gynecomastia during an anabolic steroid cycle that includes the use of aromatizable anabolic steroids, or to act as an interceptive medication immediately after the onset of gynecomastia. Raloxifene doses are the same in both instances, ranging from 30 to 60 mg per day, with the most frequent dose being 30 mg.

It is essential to emphasize that the usage of Raloxiheal during an anabolic steroid cycle may negatively affect performance, muscle growth, and strength. Raloxifene, like Nolvadex, has been shown to reduce blood IGF-1 (Insulin-like Growth Factor 1) levels, a crucial modulator of muscle development responsible for higher nitrogen retention, protein synthesis, and new muscle cell growth/a>. Examining IGF-1 levels before and after treatment with Raloxifene, additional studies revealed a statistically significant decrease in IGF-1 levels.

Consequently, SERMs like Raloxiheal and Nolvadex, which reduce blood plasma levels of essential growth hormones, have a detrimental effect on muscle growth (namely, IGF-1). As a result, it is recommended that the duration of Raloxifene administration, regardless of the purpose (PCT or gynecomastia control/reduction), be as brief as possible to prevent any Estrogen-related adverse effects connected with the use of aromatizable anabolic steroids. While short-term administration of Raloxiheal is unlikely to have a significant effect on muscle growth and function, long-term administration would have a detrimental effect on muscle growth and function. In one study of long-term Raloxifene usage, after 24 months of medication, the IGF-1 levels of test individuals were considerably lower than those of controls. In another research comparing the effects of Raloxiheal / Raloxifene and Tamoxifen (Nolvadex) on males, Raloxifene was shown to have no significant effect on IGF-1 when compared to Nolvadex[8]. In one investigation involving acromegaly, 120mg of Raloxifene was administered twice daily (in split doses of 60mg twice day), resulting in a 16% decrease in IGF-1 levels [9]. In view of the small number of studies that did not demonstrate statistically significant decreases in IGF-1 levels, any future anabolic steroid user should consider the impact of Raloxifene doses.

Consequently, SERMs like Raloxiheal and Nolvadex, which reduce blood plasma levels of essential growth hormones, have a detrimental effect on muscle growth (namely, IGF-1). As a result, it is recommended that the duration of Raloxifene administration, regardless of the purpose (PCT or gynecomastia control/reduction), be as brief as possible to prevent any Estrogen-related adverse effects connected with the use of aromatizable anabolic steroids. While short-term Raloxifene administration is unlikely to have a significant effect on muscle growth and function, long-term administration would have a detrimental influence on muscle growth and function. In one study of long-term Raloxifene usage, after 24 months of medication, the IGF-1 levels of test individuals were considerably lower than those of controls[7]. In another research comparing the effects of Raloxifene and Tamoxifen (Nolvadex) on males, Raloxifene was shown to have no significant effect on IGF-1 compared to Nolvadex. In one investigation involving acromegaly, 120mg of Raloxifene was administered twice daily (in split doses of 60mg twice day), resulting in a 16% decrease in IGF-1 levels. In view of the small number of studies that did not demonstrate statistically significant decreases in IGF-1 levels, any future anabolic steroid user should consider the impact of Raloxifene doses.